Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Other Non-Current Liabilities: 2013-2024

Historic Other Non-Current Liabilities for ImmunityBio (IBRX) over the last 9 years, with Dec 2024 value amounting to $26.1 million.

  • ImmunityBio's Other Non-Current Liabilities rose 499.07% to $115.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.2 million, marking a year-over-year increase of 499.07%. This contributed to the annual value of $26.1 million for FY2024, which is 78.01% down from last year.
  • As of FY2024, ImmunityBio's Other Non-Current Liabilities stood at $26.1 million, which was down 78.01% from $118.8 million recorded in FY2023.
  • In the past 5 years, ImmunityBio's Other Non-Current Liabilities ranged from a high of $118.8 million in FY2023 and a low of $411,000 during FY2021.
  • Its 3-year average for Other Non-Current Liabilities is $55.5 million, with a median of $26.1 million in 2024.
  • Per our database at Business Quant, ImmunityBio's Other Non-Current Liabilities surged by 5,164.23% in 2022 and then slumped by 78.01% in 2024.
  • Yearly analysis of 5 years shows ImmunityBio's Other Non-Current Liabilities stood at $1.0 million in 2020, then slumped by 60.29% to $411,000 in 2021, then soared by 5,164.23% to $21.6 million in 2022, then surged by 448.95% to $118.8 million in 2023, then plummeted by 78.01% to $26.1 million in 2024.